Application of a life table approach to assess duration of BNT162b2 vaccine-derived immunity by age using COVID-19 case surveillance data during the Omicron variant period

Background SARS-CoV-2 Omicron variants have the potential to impact vaccine effectiveness and duration of vaccine-derived immunity. We analyzed U.S. multi-jurisdictional COVID-19 vaccine breakthrough surveillance data to examine potential waning of protection against SARS-CoV-2 infection for the Pfi...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	PloS one Ročník 18; číslo 9; s. e0291678
Hlavní autoři:	Sternberg, Maya R., Johnson, Amelia, King, Justice, Ali, Akilah R., Linde, Lauren, Awofeso, Abiola O., Baker, Jodee S., Bayoumi, Nagla S., Broadway, Steven, Busen, Katherine, Chang, Carolyn, Cheng, Iris, Cima, Mike, Collingwood, Abi, Dorabawila, Vajeera, Drenzek, Cherie, Fleischauer, Aaron, Gent, Ashley, Hartley, Amanda, Hicks, Liam, Hoskins, Mikhail, Jara, Amanda, Jones, Amanda, Khan, Saadiah I., Kamal-Ahmed, Ishrat, Kangas, Sarah, Kanishka, FNU, Kleppinger, Alison, Kocharian, Anna, León, Tomás M., Link-Gelles, Ruth, Lyons, B. Casey, Masarik, John, May, Andrea, McCormick, Donald, Meyer, Stephanie, Milroy, Lauren, Morris, Keeley J., Nelson, Lauren, Omoike, Enaholo, Patel, Komal, Pietrowski, Michael, Pike, Melissa A., Pilishvili, Tamara, Peterson Pompa, Xandy, Powell, Charles, Praetorius, Kevin, Rosenberg, Eli, Schiller, Adam, Smith-Coronado, Mayra L., Stanislawski, Emma, Strand, Kyle, Tilakaratne, Buddhi P., Vest, Hailey, Wiedeman, Caleb, Zaldivar, Allison, Silk, Benjamin, Scobie, Heather M.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	San Francisco Public Library of Science 20.09.2023 Public Library of Science (PLoS)
Témata:	Age Age groups Biology and Life Sciences COVID-19 COVID-19 vaccines Disease control Disease prevention FDA approval Health surveillance Immunity Immunization Infections Jurisdiction Medicine and Health Sciences People and Places Public health Reduction Severe acute respiratory syndrome coronavirus 2 Surveillance Survival analysis Tables (data) Vaccine efficacy Vaccines United States > US
ISSN:	1932-6203, 1932-6203
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Background SARS-CoV-2 Omicron variants have the potential to impact vaccine effectiveness and duration of vaccine-derived immunity. We analyzed U.S. multi-jurisdictional COVID-19 vaccine breakthrough surveillance data to examine potential waning of protection against SARS-CoV-2 infection for the Pfizer-BioNTech (BNT162b) primary vaccination series by age. Methods Weekly numbers of SARS-CoV-2 infections during January 16, 2022–May 28, 2022 were analyzed by age group from 22 U.S. jurisdictions that routinely linked COVID-19 case surveillance and immunization data. A life table approach incorporating line-listed and aggregated COVID-19 case datasets with vaccine administration and U.S. Census data was used to estimate hazard rates of SARS-CoV-2 infections, hazard rate ratios (HRR) and percent reductions in hazard rate comparing unvaccinated people to people vaccinated with a Pfizer-BioNTech primary series only, by age group and time since vaccination. Results The percent reduction in hazard rates for persons 2 weeks after vaccination with a Pfizer-BioNTech primary series compared with unvaccinated persons was lowest among children aged 5–11 years at 35.5% (95% CI: 33.3%, 37.6%) compared to the older age groups, which ranged from 68.7%–89.6%. By 19 weeks after vaccination, all age groups showed decreases in the percent reduction in the hazard rates compared with unvaccinated people; with the largest declines observed among those aged 5–11 and 12–17 years and more modest declines observed among those 18 years and older. Conclusions The decline in vaccine protection against SARS-CoV-2 infection observed in this study is consistent with other studies and demonstrates that national case surveillance data were useful for assessing early signals in age-specific waning of vaccine protection during the initial period of SARS-CoV-2 Omicron variant predominance. The potential for waning immunity during the Omicron period emphasizes the importance of continued monitoring and consideration of optimal timing and provision of booster doses in the future.
AbstractList	Background SARS-CoV-2 Omicron variants have the potential to impact vaccine effectiveness and duration of vaccine-derived immunity. We analyzed U.S. multi-jurisdictional COVID-19 vaccine breakthrough surveillance data to examine potential waning of protection against SARS-CoV-2 infection for the Pfizer-BioNTech (BNT162b) primary vaccination series by age. Methods Weekly numbers of SARS-CoV-2 infections during January 16, 2022–May 28, 2022 were analyzed by age group from 22 U.S. jurisdictions that routinely linked COVID-19 case surveillance and immunization data. A life table approach incorporating line-listed and aggregated COVID-19 case datasets with vaccine administration and U.S. Census data was used to estimate hazard rates of SARS-CoV-2 infections, hazard rate ratios (HRR) and percent reductions in hazard rate comparing unvaccinated people to people vaccinated with a Pfizer-BioNTech primary series only, by age group and time since vaccination. Results The percent reduction in hazard rates for persons 2 weeks after vaccination with a Pfizer-BioNTech primary series compared with unvaccinated persons was lowest among children aged 5–11 years at 35.5% (95% CI: 33.3%, 37.6%) compared to the older age groups, which ranged from 68.7%–89.6%. By 19 weeks after vaccination, all age groups showed decreases in the percent reduction in the hazard rates compared with unvaccinated people; with the largest declines observed among those aged 5–11 and 12–17 years and more modest declines observed among those 18 years and older. Conclusions The decline in vaccine protection against SARS-CoV-2 infection observed in this study is consistent with other studies and demonstrates that national case surveillance data were useful for assessing early signals in age-specific waning of vaccine protection during the initial period of SARS-CoV-2 Omicron variant predominance. The potential for waning immunity during the Omicron period emphasizes the importance of continued monitoring and consideration of optimal timing and provision of booster doses in the future. SARS-CoV-2 Omicron variants have the potential to impact vaccine effectiveness and duration of vaccine-derived immunity. We analyzed U.S. multi-jurisdictional COVID-19 vaccine breakthrough surveillance data to examine potential waning of protection against SARS-CoV-2 infection for the Pfizer-BioNTech (BNT162b) primary vaccination series by age.BACKGROUNDSARS-CoV-2 Omicron variants have the potential to impact vaccine effectiveness and duration of vaccine-derived immunity. We analyzed U.S. multi-jurisdictional COVID-19 vaccine breakthrough surveillance data to examine potential waning of protection against SARS-CoV-2 infection for the Pfizer-BioNTech (BNT162b) primary vaccination series by age.Weekly numbers of SARS-CoV-2 infections during January 16, 2022-May 28, 2022 were analyzed by age group from 22 U.S. jurisdictions that routinely linked COVID-19 case surveillance and immunization data. A life table approach incorporating line-listed and aggregated COVID-19 case datasets with vaccine administration and U.S. Census data was used to estimate hazard rates of SARS-CoV-2 infections, hazard rate ratios (HRR) and percent reductions in hazard rate comparing unvaccinated people to people vaccinated with a Pfizer-BioNTech primary series only, by age group and time since vaccination.METHODSWeekly numbers of SARS-CoV-2 infections during January 16, 2022-May 28, 2022 were analyzed by age group from 22 U.S. jurisdictions that routinely linked COVID-19 case surveillance and immunization data. A life table approach incorporating line-listed and aggregated COVID-19 case datasets with vaccine administration and U.S. Census data was used to estimate hazard rates of SARS-CoV-2 infections, hazard rate ratios (HRR) and percent reductions in hazard rate comparing unvaccinated people to people vaccinated with a Pfizer-BioNTech primary series only, by age group and time since vaccination.The percent reduction in hazard rates for persons 2 weeks after vaccination with a Pfizer-BioNTech primary series compared with unvaccinated persons was lowest among children aged 5-11 years at 35.5% (95% CI: 33.3%, 37.6%) compared to the older age groups, which ranged from 68.7%-89.6%. By 19 weeks after vaccination, all age groups showed decreases in the percent reduction in the hazard rates compared with unvaccinated people; with the largest declines observed among those aged 5-11 and 12-17 years and more modest declines observed among those 18 years and older.RESULTSThe percent reduction in hazard rates for persons 2 weeks after vaccination with a Pfizer-BioNTech primary series compared with unvaccinated persons was lowest among children aged 5-11 years at 35.5% (95% CI: 33.3%, 37.6%) compared to the older age groups, which ranged from 68.7%-89.6%. By 19 weeks after vaccination, all age groups showed decreases in the percent reduction in the hazard rates compared with unvaccinated people; with the largest declines observed among those aged 5-11 and 12-17 years and more modest declines observed among those 18 years and older.The decline in vaccine protection against SARS-CoV-2 infection observed in this study is consistent with other studies and demonstrates that national case surveillance data were useful for assessing early signals in age-specific waning of vaccine protection during the initial period of SARS-CoV-2 Omicron variant predominance. The potential for waning immunity during the Omicron period emphasizes the importance of continued monitoring and consideration of optimal timing and provision of booster doses in the future.CONCLUSIONSThe decline in vaccine protection against SARS-CoV-2 infection observed in this study is consistent with other studies and demonstrates that national case surveillance data were useful for assessing early signals in age-specific waning of vaccine protection during the initial period of SARS-CoV-2 Omicron variant predominance. The potential for waning immunity during the Omicron period emphasizes the importance of continued monitoring and consideration of optimal timing and provision of booster doses in the future. Background SARS-CoV-2 Omicron variants have the potential to impact vaccine effectiveness and duration of vaccine-derived immunity. We analyzed U.S. multi-jurisdictional COVID-19 vaccine breakthrough surveillance data to examine potential waning of protection against SARS-CoV-2 infection for the Pfizer-BioNTech (BNT162b) primary vaccination series by age. Methods Weekly numbers of SARS-CoV-2 infections during January 16, 2022–May 28, 2022 were analyzed by age group from 22 U.S. jurisdictions that routinely linked COVID-19 case surveillance and immunization data. A life table approach incorporating line-listed and aggregated COVID-19 case datasets with vaccine administration and U.S. Census data was used to estimate hazard rates of SARS-CoV-2 infections, hazard rate ratios (HRR) and percent reductions in hazard rate comparing unvaccinated people to people vaccinated with a Pfizer-BioNTech primary series only, by age group and time since vaccination. Results The percent reduction in hazard rates for persons 2 weeks after vaccination with a Pfizer-BioNTech primary series compared with unvaccinated persons was lowest among children aged 5–11 years at 35.5% (95% CI: 33.3%, 37.6%) compared to the older age groups, which ranged from 68.7%–89.6%. By 19 weeks after vaccination, all age groups showed decreases in the percent reduction in the hazard rates compared with unvaccinated people; with the largest declines observed among those aged 5–11 and 12–17 years and more modest declines observed among those 18 years and older. Conclusions The decline in vaccine protection against SARS-CoV-2 infection observed in this study is consistent with other studies and demonstrates that national case surveillance data were useful for assessing early signals in age-specific waning of vaccine protection during the initial period of SARS-CoV-2 Omicron variant predominance. The potential for waning immunity during the Omicron period emphasizes the importance of continued monitoring and consideration of optimal timing and provision of booster doses in the future. BackgroundSARS-CoV-2 Omicron variants have the potential to impact vaccine effectiveness and duration of vaccine-derived immunity. We analyzed U.S. multi-jurisdictional COVID-19 vaccine breakthrough surveillance data to examine potential waning of protection against SARS-CoV-2 infection for the Pfizer-BioNTech (BNT162b) primary vaccination series by age.MethodsWeekly numbers of SARS-CoV-2 infections during January 16, 2022-May 28, 2022 were analyzed by age group from 22 U.S. jurisdictions that routinely linked COVID-19 case surveillance and immunization data. A life table approach incorporating line-listed and aggregated COVID-19 case datasets with vaccine administration and U.S. Census data was used to estimate hazard rates of SARS-CoV-2 infections, hazard rate ratios (HRR) and percent reductions in hazard rate comparing unvaccinated people to people vaccinated with a Pfizer-BioNTech primary series only, by age group and time since vaccination.ResultsThe percent reduction in hazard rates for persons 2 weeks after vaccination with a Pfizer-BioNTech primary series compared with unvaccinated persons was lowest among children aged 5-11 years at 35.5% (95% CI: 33.3%, 37.6%) compared to the older age groups, which ranged from 68.7%-89.6%. By 19 weeks after vaccination, all age groups showed decreases in the percent reduction in the hazard rates compared with unvaccinated people; with the largest declines observed among those aged 5-11 and 12-17 years and more modest declines observed among those 18 years and older.ConclusionsThe decline in vaccine protection against SARS-CoV-2 infection observed in this study is consistent with other studies and demonstrates that national case surveillance data were useful for assessing early signals in age-specific waning of vaccine protection during the initial period of SARS-CoV-2 Omicron variant predominance. The potential for waning immunity during the Omicron period emphasizes the importance of continued monitoring and consideration of optimal timing and provision of booster doses in the future.
Author	Meyer, Stephanie Pietrowski, Michael Khan, Saadiah I. Scobie, Heather M. Omoike, Enaholo Smith-Coronado, Mayra L. King, Justice León, Tomás M. Collingwood, Abi Baker, Jodee S. Ali, Akilah R. Kocharian, Anna Milroy, Lauren Pilishvili, Tamara Praetorius, Kevin Masarik, John Hicks, Liam May, Andrea Strand, Kyle Cheng, Iris Silk, Benjamin Hoskins, Mikhail Linde, Lauren Kangas, Sarah Drenzek, Cherie Hartley, Amanda Jones, Amanda Busen, Katherine Gent, Ashley Patel, Komal Cima, Mike Jara, Amanda McCormick, Donald Awofeso, Abiola O. Morris, Keeley J. Chang, Carolyn Tilakaratne, Buddhi P. Kamal-Ahmed, Ishrat Vest, Hailey Kleppinger, Alison Nelson, Lauren Zaldivar, Allison Rosenberg, Eli Wiedeman, Caleb Bayoumi, Nagla S. Link-Gelles, Ruth Broadway, Steven Peterson Pompa, Xandy Sternberg, Maya R. Dorabawila, Vajeera Fleischauer, Aaron Pike, Melissa A. Stanislawski, Emma Kanishka, FNU Schiller, Adam Lyons, B. Casey Powell, Charles Johnson, Amelia
AuthorAffiliation	15 Division of Public Health, Nebraska Department of Health and Human Services, Lincoln, Nebraska, United States of America 17 Epidemiology and Infectious Disease Section, Connecticut Department of Public Health, Hartford, Connecticut, United States of America 24 CDC Foundation, Atlanta, Georgia, United States of America 23 Disease Control and Public Health Response Division, Colorado Department of Public Health and Environment, Denver, Colorado, United States of America 4 Communicable Disease Service, New Jersey Department of Health, Trenton, New Jersey, United States of America 25 Epidemiology and Response Division, New Mexico Department of Health, Santa Fe, New Mexico, United States of America 21 Disease Epidemiology and Prevention Division, Indiana Department of Health, Indianapolis, Indiana, United States of America 22 Division of Disease Control, Philadelphia Department of Public Health, Philadelphia, Pennsylvania, United States of America Touro University, UNITED STATES 19 Bureau of Epid
AuthorAffiliation_xml	– name: 7 Communicable Disease Service, New York City Department of Health and Mental Hygiene, Long Island City, New York, United States of America – name: 15 Division of Public Health, Nebraska Department of Health and Human Services, Lincoln, Nebraska, United States of America – name: 10 Bureau of Surveillance and Data Systems, Division of Epidemiology, Albany, New York State Department of Health, New York, NY, United States of America – name: 11 Acute Epidemiology, Georgia Department of Public Health, Atlanta, Georgia, United States of America – name: 12 Communicable and Environmental Diseases and Emergency Preparedness, Nashville, Tennessee Department of Health, Nashville, Tennessee, United States of America – name: 14 Communicable Disease, North Carolina Department of Health and Human Services, Raleigh, North Carolina, United States of America – name: 5 Division of Disease Control and Health Protection, Florida Department of Health, Tallahassee, Florida, United States of America – name: 23 Disease Control and Public Health Response Division, Colorado Department of Public Health and Environment, Denver, Colorado, United States of America – name: 2 Community Health Administration, DC Department of Health, Washington, District of Columbia, United States of America – name: 3 Division of Population Health, Utah Department of Health and Human Services, Salt Lake City, Utah, United States of America – name: 6 Division of Communicable Disease, Michigan Department of Health and Human Services, Lansing, Michigan, United States of America – name: 1 COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America – name: 13 Bureau of Infectious Disease and Services, Arizona Department of Health Services, Phoenix, Arizona, United States of America – name: Touro University, UNITED STATES – name: 8 Bureau of Immunization, New York City Department of Health and Mental Hygiene, Long Island City, New York, United States of America – name: 25 Epidemiology and Response Division, New Mexico Department of Health, Santa Fe, New Mexico, United States of America – name: 16 COVID-19 Data and Surveillance Unit, Wisconsin Department of Health Services, Madison, Wisconsin, United States of America – name: 19 Bureau of Epidemiology and Public Health Informatics, Kansas Department of Health and Environment, Kansas, Missouri, United States of America – name: 24 CDC Foundation, Atlanta, Georgia, United States of America – name: 18 Center for Infectious Diseases, California Department of Public Health, Sacramento, California, United States of America – name: 4 Communicable Disease Service, New Jersey Department of Health, Trenton, New Jersey, United States of America – name: 17 Epidemiology and Infectious Disease Section, Connecticut Department of Public Health, Hartford, Connecticut, United States of America – name: 20 Infectious Disease Epidemiology, Prevention and Control Division, Minnesota Department of Health, Saint Paul, Minnesota, United States of America – name: 22 Division of Disease Control, Philadelphia Department of Public Health, Philadelphia, Pennsylvania, United States of America – name: 9 Epidemilogy, Arkansas Department of Health, Little Rock, Arkansas, United States of America – name: 21 Disease Epidemiology and Prevention Division, Indiana Department of Health, Indianapolis, Indiana, United States of America
Author_xml	– sequence: 1 givenname: Maya R. orcidid: 0000-0001-9762-0350 surname: Sternberg fullname: Sternberg, Maya R. – sequence: 2 givenname: Amelia surname: Johnson fullname: Johnson, Amelia – sequence: 3 givenname: Justice orcidid: 0009-0000-2861-8345 surname: King fullname: King, Justice – sequence: 4 givenname: Akilah R. surname: Ali fullname: Ali, Akilah R. – sequence: 5 givenname: Lauren orcidid: 0000-0002-3843-7430 surname: Linde fullname: Linde, Lauren – sequence: 6 givenname: Abiola O. surname: Awofeso fullname: Awofeso, Abiola O. – sequence: 7 givenname: Jodee S. surname: Baker fullname: Baker, Jodee S. – sequence: 8 givenname: Nagla S. surname: Bayoumi fullname: Bayoumi, Nagla S. – sequence: 9 givenname: Steven orcidid: 0009-0007-2357-8509 surname: Broadway fullname: Broadway, Steven – sequence: 10 givenname: Katherine orcidid: 0009-0005-6033-6977 surname: Busen fullname: Busen, Katherine – sequence: 11 givenname: Carolyn surname: Chang fullname: Chang, Carolyn – sequence: 12 givenname: Iris surname: Cheng fullname: Cheng, Iris – sequence: 13 givenname: Mike surname: Cima fullname: Cima, Mike – sequence: 14 givenname: Abi surname: Collingwood fullname: Collingwood, Abi – sequence: 15 givenname: Vajeera surname: Dorabawila fullname: Dorabawila, Vajeera – sequence: 16 givenname: Cherie surname: Drenzek fullname: Drenzek, Cherie – sequence: 17 givenname: Aaron surname: Fleischauer fullname: Fleischauer, Aaron – sequence: 18 givenname: Ashley surname: Gent fullname: Gent, Ashley – sequence: 19 givenname: Amanda surname: Hartley fullname: Hartley, Amanda – sequence: 20 givenname: Liam surname: Hicks fullname: Hicks, Liam – sequence: 21 givenname: Mikhail surname: Hoskins fullname: Hoskins, Mikhail – sequence: 22 givenname: Amanda surname: Jara fullname: Jara, Amanda – sequence: 23 givenname: Amanda surname: Jones fullname: Jones, Amanda – sequence: 24 givenname: Saadiah I. surname: Khan fullname: Khan, Saadiah I. – sequence: 25 givenname: Ishrat surname: Kamal-Ahmed fullname: Kamal-Ahmed, Ishrat – sequence: 26 givenname: Sarah surname: Kangas fullname: Kangas, Sarah – sequence: 27 givenname: FNU surname: Kanishka fullname: Kanishka, FNU – sequence: 28 givenname: Alison surname: Kleppinger fullname: Kleppinger, Alison – sequence: 29 givenname: Anna surname: Kocharian fullname: Kocharian, Anna – sequence: 30 givenname: Tomás M. surname: León fullname: León, Tomás M. – sequence: 31 givenname: Ruth surname: Link-Gelles fullname: Link-Gelles, Ruth – sequence: 32 givenname: B. Casey orcidid: 0000-0001-7101-1581 surname: Lyons fullname: Lyons, B. Casey – sequence: 33 givenname: John orcidid: 0009-0001-0408-7196 surname: Masarik fullname: Masarik, John – sequence: 34 givenname: Andrea surname: May fullname: May, Andrea – sequence: 35 givenname: Donald surname: McCormick fullname: McCormick, Donald – sequence: 36 givenname: Stephanie surname: Meyer fullname: Meyer, Stephanie – sequence: 37 givenname: Lauren surname: Milroy fullname: Milroy, Lauren – sequence: 38 givenname: Keeley J. orcidid: 0000-0001-7028-8095 surname: Morris fullname: Morris, Keeley J. – sequence: 39 givenname: Lauren surname: Nelson fullname: Nelson, Lauren – sequence: 40 givenname: Enaholo surname: Omoike fullname: Omoike, Enaholo – sequence: 41 givenname: Komal surname: Patel fullname: Patel, Komal – sequence: 42 givenname: Michael surname: Pietrowski fullname: Pietrowski, Michael – sequence: 43 givenname: Melissa A. surname: Pike fullname: Pike, Melissa A. – sequence: 44 givenname: Tamara surname: Pilishvili fullname: Pilishvili, Tamara – sequence: 45 givenname: Xandy surname: Peterson Pompa fullname: Peterson Pompa, Xandy – sequence: 46 givenname: Charles surname: Powell fullname: Powell, Charles – sequence: 47 givenname: Kevin surname: Praetorius fullname: Praetorius, Kevin – sequence: 48 givenname: Eli surname: Rosenberg fullname: Rosenberg, Eli – sequence: 49 givenname: Adam surname: Schiller fullname: Schiller, Adam – sequence: 50 givenname: Mayra L. surname: Smith-Coronado fullname: Smith-Coronado, Mayra L. – sequence: 51 givenname: Emma surname: Stanislawski fullname: Stanislawski, Emma – sequence: 52 givenname: Kyle surname: Strand fullname: Strand, Kyle – sequence: 53 givenname: Buddhi P. surname: Tilakaratne fullname: Tilakaratne, Buddhi P. – sequence: 54 givenname: Hailey surname: Vest fullname: Vest, Hailey – sequence: 55 givenname: Caleb surname: Wiedeman fullname: Wiedeman, Caleb – sequence: 56 givenname: Allison surname: Zaldivar fullname: Zaldivar, Allison – sequence: 57 givenname: Benjamin surname: Silk fullname: Silk, Benjamin – sequence: 58 givenname: Heather M. orcidid: 0000-0002-5448-6275 surname: Scobie fullname: Scobie, Heather M.
BookMark	eNp9UkuP0zAQjtAisbvwD5CwxIVLi53EccIFLeVVaUUvC1drYo9bV2kcbKdSfxN_EqftInaFONma-R7zusouetdjlr1kdM4Kwd5u3eh76OZDCs9p3rBK1E-yS9YU-azKaXHx1_9ZdhXCllJe1FV1mf26GYbOKojW9cQZAqSzBkmEtkMCw-AdqA2JjkAIGALRo_-D_fDtjlV5m5M9KGV7nGn0do-a2N1u7G08kPZAYI1kDLZfk8Xqx_LjjDVEQUASRr9H23XQKyQaIkzSEyxukKx2VvlksgdvoY9kSMJOP8-eGugCvji_19n3z5_uFl9nt6svy8XN7UxxWsZURZFrAapmnJegEXTJa4qGQW1Ey5GhoE3JK8FTBpkpWK4rowGrhpWipcV19uqkO3QuyPNwg8zTwARnFWMJsTwhtIOtHLzdgT9IB1YeA86vJfhoVYeyyksjTKNFW5pSNQYEK5ua5S2tdN3QMmm9P7uN7Q61wj566B6IPsz0diPXbi8Z5YxRMSm8OSt493PEEOXOBoXTbNGNx8IF4zlv6gR9_Qj67_benVBpCSF4NFLZeFx7KsB2yVlOd3fPldPdyfPdJXL5iHzfyn9pvwEFA-RW
CitedBy_id	crossref_primary_10_3389_fpubh_2025_1497399
Cites_doi	10.1016/S0140-6736(21)02183-8 10.1056/NEJMoa2117128 10.1001/jama.2022.7493 10.15585/mmwr.mm7037e1 10.1056/NEJMoa2116063 10.15585/mmwr.mm7117e3 10.1101/2022.03.24.22272854 10.1056/NEJMoa2205011 10.1136/bmj-2022-072141 10.1056/NEJMc2209371 10.1001/jamanetworkopen.2022.46915 10.15585/mmwr.mm7021e3 10.15585/mmwr.mm7109e3 10.1056/NEJMoa2202826 10.15585/mmwr.mm7111e1 10.15585/mmwr.mm7034e1 10.1016/S1473-3099(22)00409-1 10.1016/j.ijid.2023.03.022 10.15585/mmwr.mm7129e1 10.1016/S0140-6736(22)01185-0 10.1056/NEJMoa2114228 10.15585/mmwr.mm7104e2 10.1093/biomet/65.1.181 10.15585/mmwr.mm7132a2 10.1056/NEJMoa2115481
ContentType	Journal Article
Copyright	This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. – notice: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	AAYXX CITATION 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PTHSS PYCSY RC3 7X8 5PM DOA
DOI	10.1371/journal.pone.0291678
DatabaseName	CrossRef ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection Agricultural & Environmental Science Collection ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Technology collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Agricultural Science Database MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Sciences (General) Public Health
DocumentTitleAlternate	Duration of BNT162b2 vaccine-derived immunity during the Omicron variant period
EISSN	1932-6203
ExternalDocumentID	2866751611 oai_doaj_org_article_624f7f9d7b4f4c9fa7149812b06d8904 PMC10511074 10_1371_journal_pone_0291678
GeographicLocations	United States--US
GeographicLocations_xml	– name: United States--US
GroupedDBID	--- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACCTH ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFFHD AFKRA AFPKN AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAIFH BAWUL BBNVY BBTPI BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO ESTFP FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI RC3 7X8 5PM ALIPV
ID	FETCH-LOGICAL-c504t-de32d7ac81554adead4580ef1a8f7b5e1e70945675ad4e1f312d6fdae69147b03
IEDL.DBID	FPL
ISICitedReferencesCount	1
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001088222800038&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1932-6203
IngestDate	Wed Aug 13 01:17:30 EDT 2025 Mon Nov 10 04:31:15 EST 2025 Tue Nov 04 02:06:13 EST 2025 Sun Nov 09 12:11:11 EST 2025 Tue Oct 07 07:42:16 EDT 2025 Tue Nov 18 20:40:17 EST 2025 Sat Nov 29 05:44:01 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	9
Language	English
License	This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. Creative Commons CC0 public domain
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c504t-de32d7ac81554adead4580ef1a8f7b5e1e70945675ad4e1f312d6fdae69147b03
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: The authors have declared that no competing interests exist.
ORCID	0000-0002-3843-7430 0009-0000-2861-8345 0000-0001-7101-1581 0000-0001-9762-0350 0000-0002-5448-6275 0009-0001-0408-7196 0000-0001-7028-8095 0009-0007-2357-8509 0009-0005-6033-6977
OpenAccessLink	http://dx.doi.org/10.1371/journal.pone.0291678
PQID	2866751611
PQPubID	1436336
ParticipantIDs	plos_journals_2866751611 doaj_primary_oai_doaj_org_article_624f7f9d7b4f4c9fa7149812b06d8904 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10511074 proquest_miscellaneous_2867152598 proquest_journals_2866751611 crossref_citationtrail_10_1371_journal_pone_0291678 crossref_primary_10_1371_journal_pone_0291678
PublicationCentury	2000
PublicationDate	2023-09-20
PublicationDateYYYYMMDD	2023-09-20
PublicationDate_xml	– month: 09 year: 2023 text: 2023-09-20 day: 20
PublicationDecade	2020
PublicationPlace	San Francisco
PublicationPlace_xml	– name: San Francisco – name: San Francisco, CA USA
PublicationTitle	PloS one
PublicationYear	2023
Publisher	Public Library of Science Public Library of Science (PLoS)
Publisher_xml	– name: Public Library of Science – name: Public Library of Science (PLoS)
References	DR Cox (pone.0291678.ref017) 1984 AG Johnson (pone.0291678.ref009) 2022; 71 C Sacco (pone.0291678.ref027) 2022; 400 KE Fleming-Dutra (pone.0291678.ref024) 2022; 327 AL Fowlkes (pone.0291678.ref030) 2022; 71 G Paz-Bailey (pone.0291678.ref003) 2021; 1 ES Rosenberg (pone.0291678.ref008) 2022; 386 KJ Rothman (pone.0291678.ref018) 1998 KE Clarke (pone.0291678.ref019) 2022; 71 AM Price (pone.0291678.ref026) 2022; 386 EJ Shircliff (pone.0291678.ref035) 2022; 71 ES Rosenberg (pone.0291678.ref007) 2021; 70 D-Y Lin (pone.0291678.ref023) 2022; 387 Y Lin (pone.0291678.ref006) 2022 MM Higdon (pone.0291678.ref022) 2022; 22 NP Klein (pone.0291678.ref029) 2022; 71 CJ Cohen-Stavi (pone.0291678.ref032) 2022; 387 FL Khan (pone.0291678.ref031) 2022; 5 Centers for Disease Control and Prevention. (pone.0291678.ref012) 2022 HM Scobie (pone.0291678.ref002) 2021; 70 SY Tartof (pone.0291678.ref004) 2021; 398 Centers for Disease Control and Prevention. (pone.0291678.ref036) 2021 SA Qasmieh (pone.0291678.ref034) R Link-Gelles (pone.0291678.ref025) 2022; 71 SW Lagakos (pone.0291678.ref016) 1978; 65 K Bodner (pone.0291678.ref033) 2023; 131 N Andrews (pone.0291678.ref020) 2022; 386 pone.0291678.ref014 pone.0291678.ref015 JM Ferdinands (pone.0291678.ref021) 2022; 379 Centers for Disease Control and Prevention. (pone.0291678.ref013) 2022 Y Goldberg (pone.0291678.ref005) 2021; 385 Centers for Disease Control and Prevention. (pone.0291678.ref010) 2021 L Veneti (pone.0291678.ref028) V Dorabawila (pone.0291678.ref011) 2022 Centers for Disease Control and Prevention. (pone.0291678.ref001) 2021; 70
References_xml	– year: 2022 ident: pone.0291678.ref011 article-title: Risk of Infection and Hospitalization Among Vaccinated and Unvaccinated Children and Adolescents in New York After the Emergence of the Omicron Variant publication-title: JAMA – ident: pone.0291678.ref015 – volume: 398 start-page: 1407 issue: 10309 year: 2021 ident: pone.0291678.ref004 article-title: Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study publication-title: Lancet doi: 10.1016/S0140-6736(21)02183-8 – start-page: 933 year: 2022 ident: pone.0291678.ref006 article-title: Effectiveness of Covid-19 Vaccines in the United States Over 9 Months: Surveillance Data from the State of North Carolina publication-title: N Engl J Med doi: 10.1056/NEJMoa2117128 – volume: 327 start-page: 2210 year: 2022 ident: pone.0291678.ref024 article-title: Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance publication-title: JAMA doi: 10.1001/jama.2022.7493 – volume: 70 start-page: 1284 year: 2021 ident: pone.0291678.ref002 article-title: Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by vaccination status—13 US jurisdictions, April 4–July 17, 2021. publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7037e1 – volume: 386 start-page: 116 year: 2022 ident: pone.0291678.ref008 article-title: Covid-19 vaccine effectiveness in New York State publication-title: N Engl J Med doi: 10.1056/NEJMoa2116063 – volume: 71 start-page: 606 year: 2022 ident: pone.0291678.ref019 article-title: Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies—United States, September 2021–February 2022. publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7117e3 – ident: pone.0291678.ref028 article-title: Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022. doi: 10.1101/2022.03.24.22272854 – volume: 387 start-page: 227 year: 2022 ident: pone.0291678.ref032 article-title: BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age publication-title: N Engl J Med doi: 10.1056/NEJMoa2205011 – volume: 379 start-page: e072141 year: 2022 ident: pone.0291678.ref021 article-title: Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study publication-title: BMJ doi: 10.1136/bmj-2022-072141 – volume: 387 start-page: 1141 year: 2022 ident: pone.0291678.ref023 article-title: Effects of Vaccination and Previous Infection on Omicron Infections in Children publication-title: N Engl J Med doi: 10.1056/NEJMc2209371 – volume: 5 start-page: e2246915 issue: 12 year: 2022 ident: pone.0291678.ref031 article-title: Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age. publication-title: JAMA Netw Open. doi: 10.1001/jamanetworkopen.2022.46915 – volume: 70 start-page: 792 year: 2021 ident: pone.0291678.ref001 article-title: COVID-19 Vaccine Breakthrough Infections Reported to CDC—United States, January 1–April 30, 2021. publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7021e3 – year: 2022 ident: pone.0291678.ref013 publication-title: COVID-19 Vaccine Breakthrough Case Investigation and Reporting – ident: pone.0291678.ref034 article-title: The prevalence of SARS-CoV-2 infection and uptake of COVID-19 antiviral treatments during the BA.2/BA.2.12.1 surge, New York City, April-May 2022. – ident: pone.0291678.ref014 – volume: 71 start-page: 352 year: 2022 ident: pone.0291678.ref029 article-title: Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years—VISION Network, 10 States, April 2021-January 2022. publication-title: MMWR Morb Mortal Wkly Rep. doi: 10.15585/mmwr.mm7109e3 – volume: 386 start-page: 1899 year: 2022 ident: pone.0291678.ref026 article-title: BNT162b2 Protection against the Omicron Variant in Children and Adolescents publication-title: N Engl J Med doi: 10.1056/NEJMoa2202826 – volume-title: Analysis of survival data year: 1984 ident: pone.0291678.ref017 – volume: 71 start-page: 422 year: 2022 ident: pone.0291678.ref030 article-title: Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years—PROTECT Cohort, July 2021-February 2022. publication-title: MMWR Morb Mortal Wkly Rep. doi: 10.15585/mmwr.mm7111e1 – volume: 70 start-page: 1150 year: 2021 ident: pone.0291678.ref007 article-title: New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status—New York, May 3–July 25, 2021. publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7034e1 – volume: 22 start-page: 1114 year: 2022 ident: pone.0291678.ref022 article-title: Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(22)00409-1 – volume-title: Information for Health Departments on Reporting Cases of COVID-19 year: 2022 ident: pone.0291678.ref012 – volume: 1 start-page: 1 year: 2021 ident: pone.0291678.ref003 article-title: Covid-19 rates by time since vaccination during Delta variant predominance. publication-title: NEJM Evid – volume-title: Rates of COVID-19 cases and deaths by vaccination status year: 2021 ident: pone.0291678.ref010 – volume: 131 start-page: 111 year: 2023 ident: pone.0291678.ref033 article-title: Observed negative vaccine effectiveness could be the canary in the coal mine for biases in observational COVID-19 studies publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2023.03.022 – volume: 71 start-page: 931 year: 2022 ident: pone.0291678.ref025 article-title: Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated—VISION Network, 10 States, December 2021-June 2022. publication-title: MMWR Morb Mortal Wkly Rep. doi: 10.15585/mmwr.mm7129e1 – volume: 400 start-page: 97 year: 2022 ident: pone.0291678.ref027 article-title: Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5–11 years in Italy: a retrospective analysis of January-April, 2022 publication-title: Lancet doi: 10.1016/S0140-6736(22)01185-0 – volume-title: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States year: 2021 ident: pone.0291678.ref036 – volume: 385 start-page: e85 year: 2021 ident: pone.0291678.ref005 article-title: Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel publication-title: N Engl J Med doi: 10.1056/NEJMoa2114228 – volume: 71 start-page: 132 year: 2022 ident: pone.0291678.ref009 article-title: COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence—25 U.S. Jurisdictions, April 4–December 25, 2021. publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7104e2 – volume: 65 start-page: 181 year: 1978 ident: pone.0291678.ref016 article-title: Models for censored survival analysis: a cone class of variable-sum models publication-title: Biometrika doi: 10.1093/biomet/65.1.181 – volume: 71 start-page: 1029 year: 2022 ident: pone.0291678.ref035 article-title: Notes from the Field: School-Based and Laboratory-Based Reporting of Positive COVID-19 Test Results Among School-Aged Children—New York, September 11, 2021–April 29, 2022. publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7132a2 – volume: 386 start-page: 340 issue: 4 year: 2022 ident: pone.0291678.ref020 article-title: Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines publication-title: N Engl J Med doi: 10.1056/NEJMoa2115481 – volume-title: Modern Epidemiology year: 1998 ident: pone.0291678.ref018
SSID	ssj0053866
Score	2.4365206
Snippet	Background SARS-CoV-2 Omicron variants have the potential to impact vaccine effectiveness and duration of vaccine-derived immunity. We analyzed U.S.... SARS-CoV-2 Omicron variants have the potential to impact vaccine effectiveness and duration of vaccine-derived immunity. We analyzed U.S. multi-jurisdictional... BackgroundSARS-CoV-2 Omicron variants have the potential to impact vaccine effectiveness and duration of vaccine-derived immunity. We analyzed U.S.... Background SARS-CoV-2 Omicron variants have the potential to impact vaccine effectiveness and duration of vaccine-derived immunity. We analyzed U.S....
SourceID	plos doaj pubmedcentral proquest crossref
SourceType	Open Website Open Access Repository Aggregation Database Enrichment Source Index Database
StartPage	e0291678
SubjectTerms	Age Age groups Biology and Life Sciences COVID-19 COVID-19 vaccines Disease control Disease prevention FDA approval Health surveillance Immunity Immunization Infections Jurisdiction Medicine and Health Sciences People and Places Public health Reduction Severe acute respiratory syndrome coronavirus 2 Surveillance Survival analysis Tables (data) Vaccine efficacy Vaccines
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQxYELojzUhYIGiQMc0saOE8fHPqjgsuVQUG-R4westCTVJrtSf1P_ZGfy2G4kpF64xt7Em_mc-UYz_oaxT9x4iZEGMjdhFQYocRLlVuSRCYkxWjv06qFrNqHm8_z6Wv_YafVFNWG9PHD_4o4zIYMK2qlSBml1MAo5PXqlMs5crnslUGQ9YzDVf4NxF2fZcFAuUfx4sMvRTV35o1ggJaK2ajuOqNPrJ33TZd1MuOa0UnLH9Vy8YM8Hzggn_Vr32RNfvWT7w65s4PMgHf3lFbs7echHQx3AwHIRPLR0PgpG-XBoazBdrhfcerWdezq_4pkoBWyMpWx75BCcG-9g0R0haW-hvAX8-gCVyv-Gs8tf388jrsGiH4Rmvdp4amCEKwKqOoX-_CMgv4TLv1T1V-GNEe1VCySuXLvX7OfF16uzb9HQjiGyaSxbfGoinDI2JwpiHEJQpnnsAzd5UGXquVcYK6YYgeCI5yHhwmXBGZ9pLlUZJ2_YXoUGOGAQp7bMpU8caddoaY1BI8fBZNphxJyEGUtG2xR20CqnlhnLokvAKYxZ-ldfkEWLwaIzFm1_ddNrdTwy_5TMvp1LStvdBcRfMeCveAx_M3ZAoBkf0BQCoadSJNJ8xg5HIP17-ON2GPc0JWpM5et1N0dRXyqNS8wnAJysdTpSLf506uBImCmml2__x797x54JZHVUICPiQ7bXrtb-PXtqN-2iWX3o9tw9wvc1aw priority: 102 providerName: Directory of Open Access Journals – databaseName: Advanced Technologies & Aerospace Database dbid: P5Z link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwELWgcEBCQAuoCwUNEgc4pE0cJ05OqC1UcNn2UFDFJXL80a60JEuSXam_iT_JTOJsuxKCA9e1dz1az4yfPTNvGHsbKSvwpoHIjWuJF5QwDjLNs0C5WKk8N3iqu77ZhJxOs4uL_Mw_uLU-rXL0ib2jNrWmN_IDnqWIbRGfRB8WPwPqGkXRVd9C4y67RywJZJhnyffRE6Mtp6kvl4tldOB3Z39RV3Y_5AiMqLnareOoZ-0nltN53W4gzs18yVsH0Mnj_xX9CXvkoSccDrqyze7Yaoc9HN7tYChH2mHb3thbeOcZqd8_Zb8Ob8LcUDtQMJ85Cx2VXcHISg5dDaoPIYNZNuu5R9PzKOUlh5XSFMQPDOr8yhqY9ZUp3TWU14BODSgD_xKOT799-RhEOWg8XqFdNitLfZFQIqBkVhjKKgFhK5z-oGTCCn8YjajqgDiba_OMfT35dH78OfBdHgKdhKLDVWNupNIZIRtlULNFkoXWRSpzskxsZCVeQRP8B3HERi6OuEmdUTbNIyHLMH7Otirc0V0GYaLLTNjYECVOLrRSwsnQqTQ3eBGP3YTF42YX2lOgUyeOedHH9SRehYatKEhFCq8iExasv7UYKED-Mf-I9Gg9lwi8-w_q5rLw_qBIOYrmciNL4YTOnZIoMYKtMkxNlodiwnZJC8cF2uJGiSZsb1SzPw-_WQ-jq6D4j6psveznSGp3laOI2YZGb8i6OVLNrnrSccTh9FQgXvx99ZfsAUcYSBk1PNxjW12ztK_Yfb3qZm3zujfP3yaySQ4 priority: 102 providerName: ProQuest
Title	Application of a life table approach to assess duration of BNT162b2 vaccine-derived immunity by age using COVID-19 case surveillance data during the Omicron variant period
URI	https://www.proquest.com/docview/2866751611 https://www.proquest.com/docview/2867152598 https://pubmed.ncbi.nlm.nih.gov/PMC10511074 https://doaj.org/article/624f7f9d7b4f4c9fa7149812b06d8904 http://dx.doi.org/10.1371/journal.pone.0291678
Volume	18
WOSCitedRecordID	wos001088222800038&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: Directory of Open Access Journals (DOAJ) customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Agricultural Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M0K dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/agriculturejournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7P dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Engineering Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7S dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PATMY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection (Proquest) customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7X7 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Materials Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KB. dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/materialsscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database (ProQuest) customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7RV dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest advanced technologies & aerospace journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: P5Z dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: BENPR dateStart: 20061201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database (Proquest) customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8C1 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PIMPY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVATS databaseName: Public Library of Science (PLoS) Journals Open Access customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: FPL dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.plos.org/publications/ providerName: Public Library of Science
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Nb9MwFLfYxgEJARtMK4zqIXGAQ0rifNg5rmUV01gXjTEVLpET21CpJFOTVtrfxD_Js5N2BDEhLu8Q28lT_Gz_nt8XIa89oQLUNBC50ZyhguL6Ds8pd4T2hYhjiae6tsUm2GTCp9M4uVUU_7Dg-8x71_7TwXVZqIFLEc4wvkV2qB9FxoVrnHxc77y4dqOoDY-7a2Tn-LFZ-k1W03lZdRBm1z_ytwNn_Ph_WX1CHrXQEo4aWdgl91SxRx4293LQhBvtkd12MVfwps04_fYp-Xl0a8aGUoOA-UwrqE1YFayzjkNdgrAmYpDLxabvcHLpRTSjsBK5MdI7EmV6pSTMbORJfQPZDeCmBcbD_huMzq9O3jteDDken1AtFytl6h4hR2CcVaEJmwSEpXD-wzgLFvhiXCRFDSYncymfkc_j48vRB6et4uDkoRvU-FWfSiZybpCLkCi5QchdpT3BNctC5SmGKmaIigu2KE_7HpWRlkJFsRewzPX3yXaBP_SAgBvmGQ-UL03KmzjIhQg0c7WIYomKtq97xF9Pbpq3Kc5NpY15au12DFWdZipSM0NpO0M94mxGXTcpPv7Rf2jkZtPXJOi2D1AU0na9pxFF1nQsWRboII-1YMgxgqnMjSSP3aBHDozUrT9QpRRll4WIv70eOVxL4t-bX22acSsw9h1RqHJp-zBTzipGFnlHgju8dluK2XebVBxxtrkKCJ7fzdgL8oAixDPeMtQ9JNv1Yqlekvv5qp5Viz7ZYhdXhk6ZpRwpH3l9sjM8niQXfXvb0bcLFunpcID0zD01lCWWfkKahF9xRHJylnz5BX1yQ-k
linkProvider	Public Library of Science
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF6VggQSAlpADRQYJJDg4NZeO177gFAfVI1aUg4B5eau91EiBTvETlB-ExK_kRk_0kZCcOqBa3bjHa9nZ77ZeTH2ypMmQEsDkRtXAg0U13cixSNHWl_KONao1W3VbEL0-9FwGH9aY7_aXBgKq2xlYiWoda7ojnyXRyFiW8Qn3vvJd4e6RpF3tW2hUbPFiVn8QJOteNc7xO_7mvOjD4ODY6fpKuCorhuUjjY-10KqiDSp1LiTQTdyjfVkZEXaNZ4RaPJ0cTEcMZ71Pa5Dq6UJYy8Qqevjc2-wmyjHBYWQieHSwEPZEYZNep4vvN2GG3YmeWZ2XI5AjJq5XVF_VZcAqqo6zosVhLsan3lF4R3d_9-26gG710Br2KvPwgZbM9kmu1vfS0KdbrXJNhphVsCbpuL224fs596lGx9yCxLGI2ugpLQyaKuuQ5mDrFzkoGfT5dz9_sALecphLhUFKeDrTFGDaBhVmTflAtIFoNAGyjC4gIOzL71Dx4tBIXyAYjadG-r7hBQBBetCnTYKCMvh7BsFS2b4YBQSWQlUkzrXj9jna9nEx2w9Qw7aYuB2VRoFxtdU8icOlJSBFa6VYaz9yPdth_ktcyWqKfFOnUbGSeW3FGjq1Z8iIZZMGpbsMGf5r0ld4uQf8_eJb5dzqUB59UM-vUgaeZeEHEmzsRZpYAMVWymQYgSTqRvqKHaDDtsirm8XKJJLpu2w7Zat_zz8cjmMopD8WzIz-ayaI6idV4wkRisnaIXW1ZFs9LUqqo52Bl2FBE_-vvoLdvt48PE0Oe31T56yOxwhL0UPcXebrZfTmXnGbql5OSqmzyvRAOz8ug_Ybx9jpzA
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF6VghASAlpADRQYJJDg4MZeP9Y-INQ2RERFaQ8FVVzM2rtbIgU72E5QfhP_gF_HjB9pIyE49cA1u_Gu1_P4ZufF2AtHag8tDURuPBVooNiuFaY8tKRxpYwihVrd1M0mxHgcnp1FJxvsV5cLQ2GVnUysBbXKU7oj7_MwQGyL-MTpmzYs4mQwfDv7blEHKfK0du00GhI50ssfaL6Vb0YD_NYvOR--Oz18b7UdBqzUt73KUtrlSsg0JK0qFZ6q54e2No4MjUh87WiB5o-PC-OIdozrcBUYJXUQOZ5IbBefe41dF2hjkuF34n_utADKkSBoU_Vc4fRbytib5ZneszmCMmrsdkkV1h0DqMLqNC_X0O56rOYl5Te8-z8f2z12p4XcsN_wyBbb0Nk2u93cV0KThrXNtlohV8KrthL36_vs5_6Fex9yAxKmE6OhonQz6KqxQ5WDrF3noObFau7B-NQJeMJhIVMKXsDXKVCzKJjUGTnVEpIloDAHyjw4h8PjT6OB5USQIqyAcl4sNPWDwh0BBfFCk04KCNfh-BsFUWb4YBQeWQVUqzpXD9jHKznEh2wzQ2raYWD7aRJ62lVUCijyUik9I2wjg0i5oeuaHnM7QovTtvQ7dSCZxrU_U6AJ2HyKmMgzbsmzx6zVv2ZN6ZN_zD8gGl7NpcLl9Q95cR63cjAOOG7NREoknvHSyEiBO0aQmdiBCiPb67Ed4oBugTK-IOAe2-1I_M_Dz1fDKCLJ7yUznc_rOYLafEW4xXCNm9b2uj6STb7WxdbR_qArEu_R31d_xm4iX8UfRuOjx-wWRyRMQUXc3mWbVTHXT9iNdFFNyuJpLSWAfblq_voNqZOwIw
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Application+of+a+life+table+approach+to+assess+duration+of+BNT162b2+vaccine-derived+immunity+by+age+using+COVID-19+case+surveillance+data+during+the+Omicron+variant+period&rft.jtitle=PloS+one&rft.au=Sternberg%2C+Maya+R.&rft.au=Johnson%2C+Amelia&rft.au=King%2C+Justice&rft.au=Ali%2C+Akilah+R.&rft.date=2023-09-20&rft.pub=Public+Library+of+Science&rft.eissn=1932-6203&rft.volume=18&rft.issue=9&rft_id=info:doi/10.1371%2Fjournal.pone.0291678&rft.externalDocID=PMC10511074
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon